Adverse reactions: evaluated in 1645 postmenopausal women with osteoporosis1

TYMLOS was evaluated in a randomized, multicenter, double-blind, placebo-controlled clinical study in postmenopausal women with osteoporosis randomized to receive TYMLOS (n=824) or placebo (n=821) for 18 months1

Adverse reactions reported by patients treated with TYMLOS vs placebo

These data represent the most common ARs in the study; ARs were generally not present at baseline, occurred more commonly
with TYMLOS than with placebo, and occurred in at least 2% of the patients treated with TYMLOS.1

  • The incidence of serious adverse events (SAEs) was 10% (TYMLOS) and 11% (placebo)1
    • There were no discernible differences in SAEs between treatment groups2
    • No single SAE occurred in >0.5% of patients in the TYMLOS or placebo groups2
    • None of the SAEs were classified by investigators as being related to the study medication in the TYMLOS or placebo groups2

Discontinuation rates1

  • Discontinuation rates due to adverse events were 10% (TYMLOS) and 6% (placebo)
    • In the TYMLOS group, the most common ARs leading to drug discontinuation were nausea (2%), dizziness (1%), headache (1%), and palpitations (1%)

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. Data on file. Clinical Study Report BA058-05-003. Waltham, MA: Radius Health, Inc; 2017.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    10/17.   TYM-US-00647

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 10/17.
TYM-US-00647